{
  "source": "PA-Med-Nec-Glumetza.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2027-17\nProgram Prior Authorization/Medical Necessity\nMedication/Therapeutic Glumetza® (metformin extended-release modified release, brand and\nClass generic)* and metformin osmotic extended-release (generic Fortamet®)*\nP&T Approval Date 5/2014, 11/2014, 7/2015, 10/2015, 3/2016, 4/2017, 6/2017, 8/2018, 9/2019,\n10/2020, 11/2021, 2/2022, 2/2023, 2/2024, 4/2025\nEffective Date 7/1/2025\n1. Background:\nAccording to the American Diabetes Association (ADA) metformin is the preferred initial\npharmacological agent for type 2 diabetes if not contraindicated. Metformin osmotic extended-\nrelease (generic Fortamet), metformin extended-release (generic Glucophage XR) and\nGlumetza (metformin extended-release modified release) only differ in their extended-release\nformulation technology and excipient content. Treatment guidelines do not specify which\nmetformin formulation should be selected for diabetes management.\nThis program requires a member to try metformin immediate-release (generic Glucophage) and\nmetformin extended-release (generic Glucophage XR) prior to receiving coverage for\nmetformin osmotic extended-release (generic Fortamet)* and also requires an additional trial of\nmetformin osmotic extended-release (generic Fortamet)* prior to receiving coverage for\nGlumetza*.\n2. Coverage Criteriaa,b:\nA. Authorization\n1. Metformin osmotic extended-release (generic Fortamet)* will be approved based on\nall of the following criteria:\na. History of greater than or equal to 12 week trialc of metformin extended-release\n(generic Glucophage XR)\n-AND-\nb. One of the following:\n(1) Submission of medical records (e.g. chart notes, laboratory values) documenting\nan inadequate response to metformin extended-release (generic Glucophage XR)\nas evidenced by the following:\ni. For patients with diabetes diagnosis, the Hemoglobin A1c level is above\npatients’ goal\n-OR-\n© 2025 UnitedHealthcare Services, Inc.\n1\n(2) Submission of medi",
    "ophage XR)\nas evidenced by the following:\ni. For patients with diabetes diagnosis, the Hemoglobin A1c level is above\npatients’ goal\n-OR-\n© 2025 UnitedHealthcare Services, Inc.\n1\n(2) Submission of medical records (e.g. chart notes, laboratory values) documenting\nan intolerance to metformin extended-release (generic Glucophage XR) which is\nunable to be resolved with attempts to minimize the adverse effects where\nappropriate (e.g. dose reduction).\n-AND-\nc. History of greater than or equal to 12 week trialc of metformin immediate- release\n-AND-\nd. One of the following:\n(1) Submission of medical records (e.g. chart notes, laboratory values) documenting\nan inadequate response to metformin immediate-release as evidenced by the\nfollowing:\ni. For patients with diabetes diagnosis, the Hemoglobin A1c level is above\npatients’ goal\n-OR-\n(2) Submission of medical records (e.g. chart notes, laboratory values) documenting\nan intolerance to metformin immediate-release which is unable to be resolved\nwith attempts to minimize the adverse effects where appropriate (e.g. dose\nreduction).\n2. Glumetza* will be approved based on all of the following criteria:\na. Submission of article(s) published in the peer-reviewed medical literature showing\nthat the requested drug is likely to be more efficacious to this patient than metformin\nextended-release (generic Glucophage XR)\n-AND-\nb. History of greater than or equal to 12 week trialc of metformin extended-release\n(generic Glucophage XR).\n-AND-\nc. One of the following:\n(1) Submission of medical records (e.g. chart notes, laboratory values) documenting\nan inadequate response to metformin extended-release (generic Glucophage XR)\nas evidenced by the following:\ni. For patients with diabetes diagnosis, the Hemoglobin A1c level is above\npatients goal\n© 2025 UnitedHealthcare Services, Inc.\n2\n-OR-\n(2) Submission of medical records (e.g. chart notes, laboratory values) documenting\nan intolerance to metformin extended-release (generic Glucophage XR) which",
    "25 UnitedHealthcare Services, Inc.\n2\n-OR-\n(2) Submission of medical records (e.g. chart notes, laboratory values) documenting\nan intolerance to metformin extended-release (generic Glucophage XR) which is\nunable to be resolved with attempts to minimize the adverse effects where\nappropriate (e.g. dose reduction).\n-AND-\nd. History of greater than or equal to 12 week trialc of metformin osmotic extended-\nrelease (generic Fortamet).\n-AND-\ne. One of the following:\n(1) Submission of medical records (e.g. chart notes, laboratory values) documenting\nan inadequate response to metformin osmotic extended-release (generic\nFortamet) as evidenced by the following:\ni. For patients with diabetes diagnosis, the Hemoglobin A1c level is above\npatients goal\n-OR-\n(2) Submission of medical records (e.g. chart notes, laboratory values) documenting\nan intolerance to metformin osmotic extended-release (generic Fortamet) which\nis unable to be resolved with attempts to minimize the adverse effects where\nappropriate (e.g. dose reduction).\n-AND-\nf. History of greater than or equal to 12 week trialc of metformin immediate- release\n-AND-\ng. One of the following:\n(1) Submission of medical records (e.g. chart notes, laboratory values) documenting\nan inadequate response to metformin immediate-release as evidenced by the\nfollowing:\ni. For patients with diabetes diagnosis, the Hemoglobin A1c level is above\npatients goal\n-OR-\n(2) Submission of medical records (e.g. chart notes, laboratory values) documenting\nan intolerance to metformin immediate-release which is unable to be resolved\n© 2025 UnitedHealthcare Services, Inc.\n3\nwith attempts to minimize the adverse effects where appropriate (e.g. dose\nreduction).\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply\nb In Florida, Maine, and Tennessee only, medicati",
    "irements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply\nb In Florida, Maine, and Tennessee only, medications prescribed for diabetes may be approved based\non both of the following: 1) Provider attests use of this product is medically necessary for the\ntreatment of diabetes; and- 2) If applicable, clinical characteristics exist that preclude the use of the\ncovered preferred alternative(s) and use of the covered preferred alternative(s) could result in\nworsening of patient’s condition or inadequate treatment (document alternatives and clinical\ninformation related to worsening/inadequate treatment).\nc For Connecticut, Kentucky and Mississippi business, only a 30-day trial will be required.\n*Typically excluded from coverage.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. American Diabetes Association. Pharmacologic Approaches to Glycemia Treatment: Standard of\nMedical Care in Diabetes - 2025. Diabetes Care 2025;48 (Supplement 1).\n2. Glumetza [package insert]. Bridgewater, NJ: Bausch Health Companies Inc; March 2024.\n3. Metformin Hydrochloride, extended release [package insert]. Fairfield, NJ: Leading Pharma,\nLLC; October 2024.\nProgram Prior Authorization/Medical Necessity - Glumetza, Metformin extended-\nrelease (generic Fortamet)\nChange Control\nDate Change\n5/2014 New program.\n11/2014 Updated to clarify trial period for Connecticut and Kentucky to comply with\nstate regulations.\n7/2015 Updated criteria to clarify submission of medical records is required.\n10/2015 Updated background information and references. Updated criteria for\nGlumetza (brand) and Fortamet (brand) to also require the trial ",
    "teria to clarify submission of medical records is required.\n10/2015 Updated background information and references. Updated criteria for\nGlumetza (brand) and Fortamet (brand) to also require the trial of metformin\nextended-release (generic Fortamet). Added criteria for submission of\nliterature to support request.\n3/2016 Updated criteria to include newly launched generic Glumetza.\n7/2016 Added Indiana and West Virginia coverage information.\n11/2016 Administrative change. Added California coverage information.\n4/2017 Annual review. References updated. State mandate reference language\nupdated.\n© 2025 UnitedHealthcare Services, Inc.\n4\n6/2017 Updated Hemoglobin A1c level requirements to be specific to the diagnosis\nof diabetes.\n8/2018 Annual review. References updated.\n9/2019 Annual review. References updated, added automation language.\n10/2020 Annual review. References updated.\n11/2021 Removed Glucophage XR from criteria as brand is no longer available.\n2/2022 Added Florida, Maine, and Tennessee mandate language. Updated state\nmandate language for CT and KY.\n2/2023 Removed Fortamet brand from criteria as it is no longer available. Updated\nstate mandate language for Mississippi. Updated references.\n2/2024 Annual review. Updated references. Updated state mandate language and\nrequirement for Connecticut.\n4/2025 Annual review. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n5"
  ]
}